Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Barbara Melosky, MD"'
Autor:
Marie-Hélène Denault, MD, MSc, Shelley Kuang, MD, FRCPC, Aria Shokoohi, BSc, Bonnie Leung, MN-NP, Mitchell Liu, MDCM, FRCPC, Eric Berthelet, MD, FRCPC, Janessa Laskin, MD, FRCPC, Sophie Sun, MD, FRCPC, Tina Zhang, MD, FRCPC, Barbara Melosky, MD, FRCPC, Cheryl Ho, MD, FRCPC
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100316- (2022)
Introduction: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and
Externí odkaz:
https://doaj.org/article/bde7a2a808be4a1aa4e9265d197f84cb
Autor:
Bruce E. Johnson, MD, Christina S. Baik, MD, Julien Mazieres, MD, Harry J.M. Groen, MD, Barbara Melosky, MD, Jürgen Wolf, MD, Fatemeh Asad Zadeh Vosta Kolaei, PhD, Wen-Hsing Wu, MS, Stefanie Knoll, PhD, Meryem Ktiouet Dawson, MD, Adam Johns, PhD, David Planchard, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100324- (2022)
Introduction: BRAF mutations are rare in patients with NSCLC, and treatment options are limited. Dabrafenib plus trametinib (dab-tram) was approved for BRAFV600-mutated advanced NSCLC (aNSCLC), based on results from a phase 2 study (NCT01336634). Thi
Externí odkaz:
https://doaj.org/article/d127605cbc444e079ca861d9fffd5178